5 articles with TerSera
Lexicon Pharmaceuticals, Inc. announced the completion of the sale of Lexicon’s rights, title and interest in XERMELO® to TerSera Therapeutics LLC.
GTCR, a leading private equity firm, announced that its TerSera Therapeutics LLC portfolio company has entered into a definitive agreement to acquire the product Xermelo® from Lexicon Pharmaceuticals, Inc. for an upfront purchase price of approximately $159 million plus potential milestone payments based on development and commercialization of Xermelo in a new indication.
Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELOLexicon to Receive Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract Cancer
Lexicon Pharmaceuticals, Inc. and TerSera Therapeutics LLC announced that they have entered into an asset purchase and sale agreement for the sale to TerSera of Lexicon’s rights, title and interest in XERMELO®.